Novartis' Xolair wins FDA nod in CIU; AbbVie starts Phase III Humira test in fingernail psoriasis;

@FiercePharma: And the top-read special report: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: Top-read FiercePharma: Tokyo hospital exec says #Novartis employees deeply involved in leukemia-drug trial. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. More | Follow @EricPFierce

@CarlyHFierce: Novartis' vaccine unit gets a badly needed booster from the U.K. Article | Follow @CarlyHFierce

> The FDA has approved Novartis' ($NVS) Xolair as a treatment for chronic idiopathic urticaria. Release

> Japan has granted regulatory approval to AstraZeneca's ($AZN) Type 2 diabetes med Forxiga. Release

> AbbVie ($ABBV) has begun Phase III trial testing for Humira as a therapy for fingernail psoriasis. Report

> England has added Celgene's ($CELG) Abraxane, Roche's ($RHHBY) Avastin and Exelixis's Cometriq to its Cancer Drugs Fund, which offers access to meds not routinely funded by its National Health Service. More

> Brazil's national health surveillance agency has given a thumbs up to Sanofi's ($SNY) multiple sclerosis drug Lemtrada. Release

> Sanofi ($SNY) has launched a new blood glucose meter that provides an estimated HbA1c value in addition to blood glucose readings. More

Medical Device News

@FierceMedDev: Who is the top med tech company in terms of revenue? Report | Follow @FierceMedDev

@MarkHFierce: Which of the big med tech manufacturers LOST revenue in 2013? Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Alcat test uncovers food sensitivities, and could provide a "balance sheet for the body." Article | Follow @EmilyWFierce

> GE finalizes $1B Thermo Fisher Scientific deal, snatches up 3 business units. More

> South Korea targets medical device industry as its latest growth engine. Item

> St. Jude aims to jump-start the cardiac device space with new pacers and defibrillator leads. Story

Biotech News

@FierceBiotech: Gilead scrambles toward hep C cure-all with next-gen combo pill. News | Follow @FierceBiotech

@JohnCFierce: Novartis chairman vows to preserve top R&D budget in retrenchment. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Story from Friday | Follow @DamianFierce

@EmilyMFierce: Guinea confirms fever is Ebola, has killed up to 59. Story via Reuters | Follow @EmilyMFierce

> Eyeing rival mAb mob, Novartis touts PhIII secukinumab psoriasis data. Article

> Celgene wins FDA approval for its blockbuster arthritis contender apremilast. More

CRO News

> AMRI bets on manufacturing with $41M Cedarburg buyout. News

> Parexel eyes Asian trials with Singapore expansion. Story

> GVK plots a $16.5M Indian expansion as it dials up its global presence. News

> TKL cuts the ribbon on a new Phase I operation. Article

> Risk-sharing researcher Evotec buys an academic pipeline. News

> CMO Recipharm plots a $142M Swedish IPO. Brief

Biotech IT News

> NY Genome Center taps IBM's Jeopardy!-winning Watson to speed data analysis. News

> Novo Nordisk edges forward with plans to spin off its IT unit. Story

> How will Google's forays into genomics play out? Article

> J&J collaboration with San Diego Supercomputer Center speeds genome analysis. Story

> Cancer gamification project analyzes 1.5M chromosomes in one month. Story

> Merck exec: Health IT apps need more scientific rigor. Brief

And Finally... All-time No. 1 pandemic killer TB still struggles to match the research funding of more high-profile causes like HIV. Story (sub. req.)

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.